The Food and Drug Administration has approved Takeda Pharmaceutical’s Xywav, the first medication designed to treat narcolepsy by addressing a root cause of the disorder. Unlike existing treatments that merely manage symptoms like excessive daytime sleepiness, Xywav targets a brain chemical crucial for regulating wakefulness. This breakthrough is anticipated to revolutionize narcolepsy treatment and potentially pave the way for improved therapies for a variety of other sleep conditions.

Analysts predict that this new class of narcolepsy drugs, including those in development by companies like Eli Lilly and Alkermes, could collectively generate over $10 billion in annual sales. Dr. Emmanuel Mignot, a Stanford University professor who spearheaded Takeda’s final studies and pioneered the underlying science, described the drug as a "complete revolution," noting its immediate impact on patients, likening the experience to "the light switch."